A Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Satralizumab in Participants With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) Encephalitis
Summary
- Eligibility
- for people ages 12 years and up (full criteria)
- Location
- at San Francisco, California and other locations
- Dates
- study startedcompletion around
- Principal Investigator
- by Jeffrey Gelfand
Description
Summary
Official Title
Keywords
Eligibility
Locations
Lead Scientist at UCSF
- Jeffrey Gelfand
Dr. Gelfand is a Professor of Neurology at UCSF. He specializes in caring for patients with a wide range of neuroinflammatory and neurodegenerative disorders. Dr. Gelfand conducts clinical research, including clinical trials, focused on advancing new treatments and restoring neurological function. Dr. Gelfand is also an award-winning medical educator. Dr. Gelfand received an A.B.
Details
- Status
- accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Hoffmann-La Roche
- ID
- NCT05503264
- Phase
- Phase 3 research study
- Study Type
- Interventional
- Participants
- Expecting 152 study participants
- Last Updated